La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Silence Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Silence Therapeutics possède un total de capitaux propres de £112.5M et une dette totale de £0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont £188.6M et de £76.1M.

Informations clés

Ratio d'endettement

UK£0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	UK£149.59m
Fonds propres	UK£112.51m
Total du passif	UK£76.13m
Total des actifs	UK£188.64m

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21

Recent updates

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SLN ( £176.4M ) dépassent ses passifs à court terme ( £17.9M ).

Passif à long terme: Les actifs à court terme de SLN ( £176.4M ) dépassent ses passifs à long terme ( £58.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SLN est sans dette.

Réduire la dette: SLN n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SLN dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: SLN dispose d'une marge de trésorerie suffisante pour 1.6 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 30.9 % chaque année.

Silence Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

Silence Therapeutics Updates on AIM Delisting

Recent updates

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Price target increased by 16% to US$49.40

Silence Therapeutics plc Announces Executive Changes

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

New major risk - Share price stability

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

New finance chief for Silence Therapeutics

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics plc announced that it has received $20 million in funding from AstraZeneca PLC

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines